BRIDGEWATER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension. According to the study results, AR-12286 was safe and well-tolerated. There were no serious side effects reported in the study; mild to moderate and transient hyperemia (eye redness) was observed in a minority of patients. In addition, the Phase 2a study achieved statistical significance in demonstrating lowered intraocular pressure (IOP) with both once-daily and twice-daily treatment. AR-12286 achieved a maximum change of mean IOP of 28% from baseline, which is comparable to, or exceeds, pressure lowering attained by the most commonly used glaucoma drugs as reported in other studies. The Company plans on submitting the full data set for presentation at an upcoming medical meeting.
